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Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs), including both
traditional nonselective NSAIDs and the selective cyclo-oxygenase
(COX)-2 inhibitors, are among the most widely used medications in
the USA. Traditional NSAIDs, although effective at relieving pain
and inflammation, are associated with a significant increase in the
risk for gastrointestinal adverse events. Throughout the 1990s
these events were estimated to result in approximately 100,000
hospitalizations and 16,500 deaths each year nationally. Recent
studies have indicated that the risk for serious NSAID gastropathy
has declined substantially during the past decade as a result of a
number of factors, including lower doses of NSAIDs, the use of
gastroprotective agents such as proton pump inhibitors and
misoprostol, and the introduction of the selective COX-2 inhibitors.
One therapeutic approach that may reduce the risk for
gastrointestinal side effects associated with traditional NSAIDs
while retaining their efficacy is the inclusion of co-therapy with a
proton pump inhibitor; these agents inhibit acid secretion and have
been demonstrated to promote ulcer healing in patients with
NSAID-related gastric ulcers. Alternatively, COX-2 selective
agents have been used to treat patients at high risk for such
events. Both nonselective and selective COX-2 inhibitors have
now been shown to be associated with an increased risk for
cardiovascular events. These studies, together with the outcomes
of the recent US Food and Drug Administration decision to require
‘black box’ warnings regarding potential cardiovascular risks
associated with NSAIDs, suggest that the use of COX-2 inhibitors
as the sole strategy for gastroprotection in patients with arthritis
and other pain syndromes must be reconsidered, particularly
among those at risk for cardiovascular events.
Introduction
The nonsteroidal anti-inflammatory drugs (NSAIDs) are
among the most widely used medications in the USA
because of their demonstrated efficacy in reducing pain and
inflammation. In the year 2000 patients in the USA alone
received more than 111 million prescriptions for these
agents. In addition, NSAIDs are the most commonly used
over-the-counter medications, with more than 30 billion
tablets sold annually. More than one-third of the elderly take
NSAIDs daily, and 70% report taking NSAIDs at least once a
week [1].
A major limiting factor in the use of traditional NSAIDs is
gastrointestinal toxicity. Endoscopic studies have demon-
strated that gastric or duodenal ulcers develop in 15–30% of
patients who regularly take NSAIDs [2]. Throughout the
1990s clinically important NSAID-related events (e.g.
bleeding, obstruction, and perforation) were estimated to
result in approximately 100,000 hospitalizations and 16,500
deaths each year nationally. Recent studies have indicated
that the risk for serious NSAID gastropathy has declined 67%
over the past decade as a result of a number of factors,
including lower doses of NSAIDs, use of gastroprotective
agents such as proton pump inhibitors (PPIs), and the
introduction of the selective cyclo-oxygenase (COX)-2
inhibitors [3-5]. Studies suggest that between US$0.66 and
US$1.25 is spent on the treatment of gastrointestinal side
effects for each US$1 spent on NSAIDs; furthermore, it has
been estimated that one-third of the cost of managing arthritis
is associated with the treatment of NSAID-related adverse
effects [6-8]. Because these agents are so widely used, the
potential scope of the health problem associated with NSAID
related gastrointestinal adverse events is substantial.
Therapeutic approaches are available that may reduce the
risk for gastrointestinal side effects associated with traditional
NSAIDs. Co-therapy with a nonselective NSAID (such as
naproxen) and a PPI, which inhibits acid secretion, has been
demonstrated to promote ulcer healing in patients with
NSAID-related gastric ulcers. Prophylactic use of PPIs in
patients with previous gastrointestinal events or in those at
high risk for such events is considered appropriate by major
treatment guidelines [9]. Clinical studies also support the
efficacy of misoprostol, a stable prostaglandin that reduces
gastric  acid secretion, as a strategy to prevent NSAID
dependent gastropathy [10,11]. However, it should be noted
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that in the report by Graham and coworkers [10], at the studied
dosage of misoprostol (800 mg/day) a significant proportion of
patients in the misoprostol group reported treatment-related
adverse events and discontinued the medication.
Alternatively, selective COX-2 NSAIDs may be used to treat
patients at high risk for gastrointestinal events. The COX-2
inhibitors have approximately half the associated gastro-
intestinal risks compared with nonselective NSAIDs. However,
important concerns have recently been raised regarding the
potential cardiovascular toxicity of the entire NSAID class,
including selective and nonselective agents [12-14].
Cardiovascular safety review of COX-2
inhibitors
In response to an emerging body of data underscoring the
possible cardiovascular risks associated with the use of
COX-2 inhibitors, a joint meeting of the US Food and Drug
Administration (FDA) Arthritis Advisory Committee and the
Drug Safety and Risk Management Advisory Committee was
held in February 2005 to examine the safety of COX-2
inhibitors and NSAIDs [15].
Safety review
The primary purpose of this hearing was to examine data on
rofecoxib, celecoxib, valdecoxib, etoricoxib, lumiracoxib, and
naproxen to determine whether these agents pose a cardio-
vascular safety risk, to evaluate the risks and benefits of each
drug, and to identify actions needed for the safe use of these
agents.
Clinical trials and population-based studies of rofecoxib
indicated that this agent is associated with increased
cardiovascular risk, particularly at higher doses [15]. Risk for
cardiovascular events is highest among patients receiving the
50 mg dose, and less so among patients receiving the 25 mg
dose and not detected among those receiving 12.5 mg. The
issue of potential cardiovascular events came into sharper focus
with the release of the Vioxx Gastrointestinal Outcomes
Research (VIGOR) trial [12], which demonstrated a significant
difference between rofecoxib 50 mg/day and naproxen 500 mg
twice daily in risk for cardiovascular thrombotic events. The
subsequent withdrawal of rofecoxib on 30 September 2004
was triggered in part by the results of the Adenomatous Polyp
Prevention on Vioxx (APPROVe) trial [16], which found that the
long-term use of the COX-2 inhibitor at 25 mg/day was
associated with an increased risk for thrombotic events, first
observed after 18 months of therapy.
For celecoxib, controlled clinical trials conducted to date
suggest that low dose celecoxib is not associated with
increased cardiovascular risk [15]. However, the majority of
these trials were of short duration; longer exposures may be
associated with increased risk. The Adenoma Prevention with
Celecoxib (APC) trial [17], which randomly assigned patients
to placebo or high dose celecoxib (400–800 mg/day) for
3 years, demonstrated dose related increases in cardio-
vascular events. An additional trial, conducted by the National
Institute on Aging in patients with Alzheimer’s disease, was
suspended after preliminary data showed a trend toward
increased risk for cardiovascular events, although the study
was too small to provide conclusive results [18]. Active
comparator trials using diclofenac or ibuprofen demonstrated
that celecoxib was not associated with increased risk
compared with these agents [14].
In contrast, the use of valdecoxib and its intravenous prodrug
parecoxib was associated with increased cardiovascular risk
in short-term studies of patients undergoing coronary artery
bypass graft surgery [15]. In one recent trial patients receiving
these agents were at 3.7-fold increased risk compared with
placebo. It should be noted that all patients in this study
received low-dose aspirin, indicating that the increased risk
occurred in the setting of dual inhibition of both COX-1 and
COX-2. Meta-analyses of short-term trials enrolling more than
12,000 patients who required treatment for arthritis or pain did
not find increased cardiovascular risk for valdecoxib in
comparison with other NSAIDs; however, higher rates of
edema and hypertension were detected at the higher doses.
For the newer agents lumiracoxib and etoricoxib, data suggest
that there may be some increase in cardiovascular risk [15]. In
a study that compared lumiracoxib with ibuprofen, no statistical
differences in cardiovascular risk were observed, although
numerically more events were observed on ibuprofen [19].
However, more cardiovascular events were observed with
lumiracoxib in comparison with naproxen. Among patients who
took concomitant low-dose aspirin, variable and inconsistent
effects on cardiovascular outcomes were observed. Similarly,
etoricoxib had a similar rate of cardiovascular events to that of
non-naproxen NSAIDs; direct comparison with naproxen
showed that etoricoxib was associated with increased
cardiovascular risk compared to naproxen [15].
Although data on the cardiovascular risks of traditional
NSAIDs are incomplete, unpublished studies presented at
the recent US FDA meeting [15] suggest an increase in risk
for cardiovascular events. The naproxen data are at odds with
meta-analyses suggesting that it might reduce risk for
cardiovascular events.
FDA Advisory Committee recommendations
Based on the data summarized above, the Committee voted
unanimously that all COX-2 inhibitors that have been
approved for use in the USA, including celecoxib, valdecoxib,
and rofecoxib, significantly increase the risk for cardiovascular
events [15]. The Committee noted that the benefits of
celecoxib outweigh potential cardiovascular risks, and voted
unanimously in favor of keeping celecoxib on the market. In
contrast, opinion was only slightly in favor of keeping
valdecoxib on the market. Just over half of the Committee
voted in favor of permitting the reintroduction of rofecoxib,S3
and many members argued that the 50 mg dosage of
rofecoxib should not be marketed. The panelists were
unanimous in recommending the addition of a ‘black box’
warning to the labeling of all COX-2 inhibitors. It was also
agreed that product labels for all traditional NSAIDs should
contain a warning regarding cardiovascular risk.
FDA mandated labeling changes
On 7 April 2005, the FDA requested that valdecoxib be
removed from the market and recommended a series of
changes to the labeling for COX-2 inhibitors and NSAIDs. A
‘black box’ warning will be added to the celecoxib label
highlighting the potential for increased cardiovascular and
gastrointestinal risk; the labels for prescription NSAIDs will be
revised to include a similar boxed warning. The labels will also
contain specific information on the potential for cardiovascular
and gastrointestinal risk. In addition, all prescribed NSAIDs will
be required to include a medication guide for patients to
advise them of the risk for cardiovascular and gastrointestinal
events. The FDA also requested that over-the-counter NSAIDs
add a warning about potential skin reactions. In a recently
issued Executive Summary Report [20], the FDA noted that it
was deemed reasonable to conclude that there is a ‘class
effect’ for increased cardiovascular risk for all NSAIDs, pending
the availability of data from long-term controlled clinical trials
that more clearly delineate risks associated with individual
agents. Data at this point do not allow one to conclude that
currently available COX-2 selective drugs confer an increased
risk over nonselective NSAIDs in chronic use.
Current treatment for pain and inflammation
The American College of Rheumatology (ACR) and the
American Pain Society have issued practice guidelines for
the management of patients with rheumatoid arthritis,
osteoarthritis (OA), and chronic pain. Although these
guidelines require revision on the basis of the recommen-
dations of the FDA Advisory Committees regarding the
NSAIDs, including the COX-2 inhibitors, it is worthwhile
presenting them here to provide a context in which to discuss
treatment decisions in light of recent regulatory events.
Current recommendations for the use of NSAIDs and
COX-2 inhibitors
Recommendations for the medical management of OA of the
hip and knee have been published by the ACR [21].
Nonpharmacologic management strategies are first-line
therapy for all patients. The ACR recommends that, when
necessary, pharmacologic therapy should be added to
continuing nonpharmacologic approaches. Recommen-
dations vary for patients with mild, moderate, or severe
disease. Acetaminophen is considered first-line pharmaco-
logic therapy for mild to moderate OA based on cost,
efficacy, and toxicity profile. Although NSAIDs can be
effective, the guidelines indicate that the relief of mild to
moderate pain afforded by acetaminophen is comparable to
that achieved using over-the-counter NSAIDs.
Currently, the ACR recommends acetaminophen as first-line
treatment for OA of the knee or hip. This is largely because of
the perception that acetaminophen is safer than NSAIDs and
is equally effective [22,23]. Until recently, few comparison
data were available with which to assess the therapeutic
equivalence of acetaminophen and NSAIDs. Results from two
older comparison studies, one comparing acetaminophen
with ibuprofen [24] and the other comparing acetaminophen
with naproxen [25], suggested that acetaminophen had
similar efficacy to NSAIDs. The results of these trials
influenced current ACR guidelines recommending first-line
use of acetaminophen.
Despite older clinical data suggesting that acetaminophen is
as effective as NSAIDs, a survey of 1799 patients found that
the majority of patients with OA (>60%) prefer NSAIDs over
acetaminophen in the symptomatic treatment of OA based on
perceived better efficacy [26]. Results from recent blinded,
randomized, placebo controlled trials comparing the efficacy
of acetaminophen and NSAIDs are consistent with this
patient preference for NSAIDs and may necessitate the
reassessment of the ACR guidelines. Results from a meta-
analysis conducted by Lee and colleagues [27] indicate that
NSAIDs are statistically superior to acetaminophen in
reducing OA pain. Using data from seven clinical trials that
evaluated both traditional and COX-2-selective agents in the
treatment of OA pain, the authors found that scores for
overall pain at rest and walking pain favored the NSAID
group. There were slightly, but not significantly, more
withdrawals due to adverse events in the NSAID group. A
second trial, conducted by Zhang and colleagues [28], found
that while acetaminophen was effective in relieving arthritis
pain, NSAIDs were significantly better in terms of pain relief,
patient preference, and clinical response.
A 2001 study of patients with OA of the hip or knee randomly
assigned to 75 mg diclofenac plus 200 µg misoprostol twice
daily or 1000 mg acetaminophen four times daily [29]
showed that the diclofenac/misoprostol combination yielded
significantly greater improvement in all primary outcome
measures (Western Ontario and McMaster Universities
Osteoarthritis Index and the visual analog pain scale of the
Multidimensional Health Assessment Questionnaire;
P < 0.001) over a 6 week period.
Recently, Geba and colleagues [30] reported that rofecoxib
25 mg/day provided greater therapeutic benefits than
maximal daily doses of 4000 mg/day of acetaminophen in
patients with OA of the knee for all prespecified end-points
(night pain, composite pain subscale, stiffness subscale, and
physical functioning subscale) and was more effective than
rofecoxib 12.5 mg/day and celecoxib200 mg/day.
The Patient Preference for Placebo, Acetaminophen (paraceta-
mol) or Celecoxib Efficacy Studies (PACES) [31] also
demonstrated that 200 mg/day celecoxib was more effective
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than acetaminophen at a dosage of 1000 mg four times daily,
with approximately twice as many patients preferring the
COX-2 inhibitor compared with acetaminophen or placebo
(P = 0.001 and P = 0.009; two 6 week crossover trials).
Prescription NSAIDs are recommended for the treatment of
moderate to severe OA; however, the guidelines strongly
recommend co-therapy with gastroprotective agents in patients
at increased risk for gastrointestinal adverse events. COX-2
selective inhibitors are associated with a somewhat better
toxicity profile, but they are still categorized as NSAIDs, with
the same risks and warnings. Patients with moderate to severe
OA may receive prescription NSAIDs with gastroprotective
agents, or COX-2 selective inhibitors as first-line therapy.
Recommendations for the treatment of pain in OA have also
been released by the American Pain Society [32]. The
guidelines indicate that acetaminophen is the medication of first
choice for mild pain. For the person with moderate to severe
pain and/or inflammation, a COX-2 inhibitor is considered first-
line therapy unless the patient is thought to be at high risk for
hypertension or renal disorder. In patients at risk for
hypertension and edema, the guidelines recommend caution
when using NSAIDs because of the risk for exacerbating these
conditions. Nonselective NSAIDs should be considered only if
the person is not responsive to or unable to take COX-2
selective NSAIDs and/or acetaminophen up to 4000 mg/day,
and only after a risk analysis is done to determine the risk for a
significant NSAID induced gastrointestinal complication. If such
risk factors exist, then a prophylactic agent such as a PPI or
misoprostol should be given along with the nonselective NSAID.
Among patients at cardiovascular risk, low-dose aspirin is
recommended; however, it should be accompanied by a
gastroprotective agent, regardless of whether the patient is
treated with a nonselective or COX-2 selective NSAID.
Evidence based consensus guidelines
Recently, evidence based consensus guidelines were
published for the use of NSAIDs, COX-2 inhibitors, and co-
therapy with PPIs in patients who require chronic anti-
inflammatory therapy [9]. These guidelines were based on a
literature review performed by the authors on the risks,
benefits, and costs of each therapy. Use in particular clinical
scenarios was rated as ‘appropriate’, ‘uncertain’, or
‘inappropriate’ on a 9 point scale by a physician panel
consisting of rheumatologists, internists, gastroenterologists,
and cardiologists.
The guidelines are summarized in Table 1 [9]. Briefly, the
panel recommended treatment with NSAIDs alone in patients
aged less than 65 years who do not have gastrointestinal risk
factors. Co-therapy with a PPI or treatment with a COX-2
inhibitor was considered unnecessary in these patients. The
use of an NSAID alone was considered inappropriate in any
patient with a previous gastrointestinal event and in those
who concurrently receive aspirin, steroids, or warfarin; these
patients should receive either a COX-2 inhibitor or an NSAID
plus a PPI. Use of a COX-2 inhibitor with PPI co-therapy was
considered appropriate only in patients at very high risk, such
as those with a previous gastrointestinal event who are taking
aspirin and those who are taking aspirin plus steroids or
warfarin. Among patients aged 65 years or older considered
at low risk for gastrointestinal events, there was uncertainty
regarding whether an NSAID or a COX-2 inhibitor could be
used alone.
Conclusion
Taken together, the results of recent clinical trials and
evidence presented at the US FDA Arthritis Advisory
Committee and the Drug Safety and Risk Management
Advisory Committee hearing [33] suggest that there is an
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Table 1
Guidelines for NSAID use
NSAID alone NSAID + PPI COX-2 COX-2 + PPI
Appropriate Age <65 years, no aspirin  On aspirin  On aspirin and no previous  Previous gastrointestinal 
and no previous  Previous gastrointestinal  gastrointestinal event  event and on aspirin 
gastrointestinal event event Not on aspirin and previous  On aspirin and 
gastrointestinal event steroids/warfarin
Inappropriate Previous gastrointestinal  Age <65 years, not on  – Not on aspirin and no 
event  aspirin and no previous  previous gastrointestinal 
On aspirin, steroids, or  gastrointestinal event event 
warfarin Age <65 years, on aspirin but 
no previous gastrointestinal 
event 
Age <65 years, previous 
uncomplicated 
gastrointestinal event and not 
on aspirin, steroids, or 
warfarin
Shown are guidelines for nonsteroidal anti-inflammatory drug (NSAID) use prior to rofecoxib withdrawal [9]. COX, cyclo-oxygenase; PPI, proton
pump inhibitor. Reproduced with permission from [9].S5
increase in cardiovascular risk associated with the use of
NSAIDs as a class. These findings have substantial
implications for public health, patient education, and
therapeutic decision making on the part of rheumatologists
and other physicians charged with managing arthritis and
related conditions.
Current guidelines for the management of pain and
inflammation in patients with OA and rheumatoid arthritis
must be revised to encompass not only the regulatory
changes proposed for COX-2 inhibitor therapy but also the
lack of benefit – and questionable safety – of acetaminophen.
The recommendations should also reflect the emerging role
of co-therapy with a nonselective NSAID and a PPI, a
combination that may offer effective pain control along with
optimal gastroprotection. Furthermore, the guidelines should
integrate assessment of cardiovascular and gastrointestinal
risk before initiation of NSAIDs or COX-2 inhibitors.
A key concern is the interaction between aspirin and NSAIDs.
Although low-dose aspirin is cardioprotective, evidence
suggests that concomitant use with certain NSAIDs – in
particular ibuprofen – may reduce its cardioprotective
benefits and increase gastrointestinal risk. Although not
sanctioned by a medical society, a clinician’s guide to NSAID
therapy following the withdrawal of rofecoxib and valdecoxib
provides initial guidance for the treatment of patients who
require NSAID therapy [34]. This treatment algorithm
accounts for recent evidence that cardiovascular risk is
increased in patients who receive NSAIDs and for data
suggesting that an NSAID plus a PPI is comparable to a
COX-2 selective agent in terms of gastrointestinal safety. The
key aspects of this algorithm are those that address
gastroprotection, especially with regard to recognition of the
added risk of ASA-induced gastric injury. Specific cardio-
vascular recommendations are premature at this time, given
the increased risk imparted by both traditional NSAIDs and
COX-2 selective agents [35].
It is clear from recent data and FDA decisions that the use of
both traditional NSAIDs and COX-2 selective agents must be
reconsidered. This supplement considers the evidence for
and against the use of NSAIDs, including COX-2 inhibitors,
with regard to gastrointestinal and cardiovascular safety, and
presents a summary of current management options for the
prevention of gastrointestinal complications in light of these
recent developments.
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